Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready
Bicara Therapeutics Inc. has 1 pending office action in Biotechnology & Pharmaceuticals. CUNNINGCHEN, KATHLEEN MARY is the listed examiner, so the prosecution record points to a focused examination relationship.
The matter sits within one art unit. Counsel can use the concentrated assignment to develop a targeted response, particularly by connecting claim language and supporting disclosure to the biotechnology or pharmaceutical issue identified in the action.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §103 only | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| CUNNINGCHEN, KATHLEEN MARY | 1 | 62.5% | +60.5% |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18256748 | PHARMACEUTICAL FORMULATIONS FOR FUSION PROTEINS | CUNNINGCHEN, KATHLEEN MARY | — |
| Art Unit | Apps |
|---|---|
| 1646 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18256748 | PHARMACEUTICAL FORMULATIONS FOR FUSION PROTEINS | CUNNINGCHEN, KATHLEEN MARY | 1646 | §103 | Final Rejection | — | Pending | Jun 09, 2023 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialBicara Therapeutics Inc. has 1 pending office actions as of October 2026, spread across 1 art units and 1 examiners.
Kathleen Mary Cunningchen has the most, with 1 of Bicara Therapeutics Inc.'s pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
